EUR 0.23
(0.09%)
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 | -16.23 Million EUR | 10.29% |
2022 | -18.1 Million EUR | -253.41% |
2021 | -15.96 Million EUR | 183.55% |
2020 | -14.12 Million EUR | 22.97% |
2019 | -18.33 Million EUR | 0.0% |
Year | EBITDA | EBITDA Growth |
---|---|---|
2023 Q1 | -4172.00 EUR | 21.87% |
2023 FY | - EUR | 10.29% |
2023 Q2 | -4172.00 EUR | 0.0% |
2022 FY | - EUR | -253.41% |
2022 Q4 | -5339.50 EUR | 0.0% |
2021 FY | - EUR | 183.55% |
2020 FY | - EUR | 22.97% |
2019 FY | - EUR | 0.0% |
Name | EBITDA | EBITDA Difference |
---|---|---|
European Medical Solutions | 59 Thousand EUR | 27622.034% |
FERMENTALG | -10.51 Million EUR | -54.5% |
argenx SE | -199.5 Million EUR | 91.861% |
BioSenic S.A. | -6.79 Million EUR | -138.935% |
Celyad Oncology SA | -7.76 Million EUR | -109.172% |
Hyloris Pharmaceuticals SA | -14.98 Million EUR | -8.398% |
Onward Medical N.V. | -35.23 Million EUR | 53.914% |
Oxurion NV | -16.72 Million EUR | 2.935% |
PHAXIAM Therapeutics S.A. | -22.93 Million EUR | 29.184% |
Financière de Tubize SA | 184.57 Thousand EUR | 8897.698% |
UCB SA | 1.26 Billion EUR | 101.28% |